Fig. 2From: Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regressionMeta-regression analysis between the differences (intervention minus placebo) in achieved HbA1c at the end of CVOTs and the corresponding hazard ratio (HR) for MACE (top) or non-fatal stroke (bottom) in patients with type 2 diabetes participating in 18 CVOTsBack to article page